Pyoderma gangrenosum after mRNA-based SARS-CoV-2 vaccine

J Eur Acad Dermatol Venereol. 2022 Dec;36(12):e969-e970. doi: 10.1111/jdv.18389. Epub 2022 Jul 11.

Authors

J Franceschi¹, A S Darrigade¹, P Sanchez-Pena², V Legrain-Lifermann³, B Milpied¹

Affiliations

¹ Department of Dermatology, Bordeaux University Hospital, Bordeaux cedex, France.
² Regional Center of Pharmacovigilance, Pharmacology Department, Bordeaux University Hospital, Bordeaux cedex, France.
³ Department of Dermatology, Dax Hospital, Dax, France.

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Humans
Pyoderma Gangrenosum* / etiology
RNA, Messenger
SARS-CoV-2

Substances

COVID-19 Vaccines
RNA, Messenger